on TME PHARMA N.V. (isin : NL0015000YE1)
TME Pharma Terminates Liquidity Contract Amid Cost Optimization
On July 8, 2025, TME Pharma N.V., a biotechnology company developing cancer and eye disease therapies, announced the termination of its liquidity contract with INVEST SECURITIES. This decision was effective from July 7, 2025, after market close.
This move aligns with TME Pharma's broader cost-cutting strategy following recent refinancing and organizational restructuring. The company aims to reduce operational expenses further to preserve cash. Improved trading volume and liquidity make the liquidity contract unnecessary.
At contract closure, the liquidity account held 85,812 shares and €14,974.69 in cash. Initially, the account, since October 2016, was funded with 10,000 shares and €100,000 in cash.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all TME PHARMA N.V. news